High-dose rituximab and anti-MAG–associated polyneuropathy
S Renaud, P Fuhr, M Gregor, K Schweikert, D Lorenz… - Neurology, 2006 - AAN Enterprises
Neurology, 2006•AAN Enterprises
Rituximab has been administered successfully in patients with polyneuropathy associated
with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-
up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750
mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with
improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.
with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-
up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750
mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with
improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.
Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.
American Academy of Neurology